U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Locally Advanced Hepatocellular Carcinoma

MedGen UID:
1710030
•Concept ID:
C5239576
•
Neoplastic Process

Definition

Hepatocellular carcinoma that has spread to nearby tissues or lymph nodes. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVLocally Advanced Hepatocellular Carcinoma

Professional guidelines

PubMed

Anti-PD-1/PD-L1 immunotherapy in conversion treatment of locally advanced hepatocellular carcinoma.
Chen J, Zhang D, Yuan Y
Clin Exp Med 2023 Jul;23(3):579-590. Epub 2022 Aug 26 doi: 10.1007/s10238-022-00873-6. PMID: 36018466
Comparison of MRI-based response criteria and radiomics for the prediction of early response to transarterial radioembolization in patients with hepatocellular carcinoma.
Aujay G, Etchegaray C, Blanc JF, Lapuyade B, Papadopoulos P, Pey MA, Bordenave L, Trillaud H, Saut O, Pinaquy JB
Diagn Interv Imaging 2022 Jul-Aug;103(7-8):360-366. Epub 2022 Feb 17 doi: 10.1016/j.diii.2022.01.009. PMID: 35183483
Evaluating Treatment Response of Radioembolization in Intermediate-Stage Hepatocellular Carcinoma Patients Using 18F-Fluoroethylcholine PET/CT.
Hartenbach M, Weber S, Albert NL, Hartenbach S, Hirtl A, Zacherl MJ, Paprottka PM, Tiling R, Bartenstein P, Hacker M, Haug AR
J Nucl Med 2015 Nov;56(11):1661-6. Epub 2015 Sep 24 doi: 10.2967/jnumed.115.158758. PMID: 26405170

Recent clinical studies

Etiology

Sequential transarterial chemoembolisation and stereotactic body radiotherapy followed by immunotherapy as conversion therapy for patients with locally advanced, unresectable hepatocellular carcinoma (START-FIT): a single-arm, phase 2 trial.
Chiang CL, Chiu KWH, Chan KSK, Lee FAS, Li JCB, Wan CWS, Dai WC, Lam TC, Chen W, Wong NSM, Cheung ALY, Lee VWY, Lau VWH, El Helali A, Man K, Kong FMS, Lo CM, Chan AC
Lancet Gastroenterol Hepatol 2023 Feb;8(2):169-178. Epub 2022 Dec 15 doi: 10.1016/S2468-1253(22)00339-9. PMID: 36529152
Arterial Chemotherapy of Oxaliplatin Plus Fluorouracil Versus Sorafenib in Advanced Hepatocellular Carcinoma: A Biomolecular Exploratory, Randomized, Phase III Trial (FOHAIC-1).
Lyu N, Wang X, Li JB, Lai JF, Chen QF, Li SL, Deng HJ, He M, Mu LW, Zhao M
J Clin Oncol 2022 Feb 10;40(5):468-480. Epub 2021 Dec 14 doi: 10.1200/JCO.21.01963. PMID: 34905388
Percutaneous ablation for locally advanced hepatocellular carcinoma with tumor portal invasion.
Blaise L, Pereira H, Vilgrain V, Sutter O, Gigante E, Walter A, Ganne-Carrié N, Nahon P, Bouattour M, Dioguardi Burgio M, Grando V, Nkontchou G, Seror O, Nault JC
Clin Res Hepatol Gastroenterol 2021 Nov;45(6):101731. Epub 2021 Jun 15 doi: 10.1016/j.clinre.2021.101731. PMID: 34139320
Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial.
Garin E, Tselikas L, Guiu B, Chalaye J, Edeline J, de Baere T, Assenat E, Tacher V, Robert C, Terroir-Cassou-Mounat M, Mariano-Goulart D, Amaddeo G, Palard X, Hollebecque A, Kafrouni M, Regnault H, Boudjema K, Grimaldi S, Fourcade M, Kobeiter H, Vibert E, Le Sourd S, Piron L, Sommacale D, Laffont S, Campillo-Gimenez B, Rolland Y; DOSISPHERE-01 Study Group
Lancet Gastroenterol Hepatol 2021 Jan;6(1):17-29. Epub 2020 Nov 7 doi: 10.1016/S2468-1253(20)30290-9. PMID: 33166497
Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial.
Vilgrain V, Pereira H, Assenat E, Guiu B, Ilonca AD, Pageaux GP, Sibert A, Bouattour M, Lebtahi R, Allaham W, Barraud H, Laurent V, Mathias E, Bronowicki JP, Tasu JP, Perdrisot R, Silvain C, Gerolami R, Mundler O, Seitz JF, Vidal V, Aubé C, Oberti F, Couturier O, Brenot-Rossi I, Raoul JL, Sarran A, Costentin C, Itti E, Luciani A, Adam R, Lewin M, Samuel D, Ronot M, Dinut A, Castera L, Chatellier G; SARAH Trial Group
Lancet Oncol 2017 Dec;18(12):1624-1636. Epub 2017 Oct 26 doi: 10.1016/S1470-2045(17)30683-6. PMID: 29107679

Diagnosis

Anti-PD-1/PD-L1 immunotherapy in conversion treatment of locally advanced hepatocellular carcinoma.
Chen J, Zhang D, Yuan Y
Clin Exp Med 2023 Jul;23(3):579-590. Epub 2022 Aug 26 doi: 10.1007/s10238-022-00873-6. PMID: 36018466
Cost-Effectiveness Analysis of Selective Internal Radiotherapy With Yttrium-90 Versus Sorafenib in Locally Advanced Hepatocellular Carcinoma.
Marqueen KE, Kim E, Ang C, Mazumdar M, Buckstein M, Ferket BS
JCO Oncol Pract 2021 Feb;17(2):e266-e277. Epub 2021 Jan 8 doi: 10.1200/OP.20.00443. PMID: 33417490Free PMC Article
Liver-directed combined radiotherapy as a bridge to curative surgery in locally advanced hepatocellular carcinoma beyond the Milan criteria.
Lee WH, Byun HK, Choi JS, Choi GH, Han DH, Joo DJ, Kim DY, Han KH, Seong J
Radiother Oncol 2020 Nov;152:1-7. Epub 2020 Jul 31 doi: 10.1016/j.radonc.2020.07.046. PMID: 32739317
Salvage Surgery for Initially Unresectable Locally Advanced Hepatocellular Carcinoma Downstaged by Hepatic Arterial Infusion Chemotherapy.
Goto Y, Hisaka T, Sakai H, Takagi K, Fukutomi S, Akagi Y, Okuda K
Anticancer Res 2020 Aug;40(8):4773-4777. doi: 10.21873/anticanres.14479. PMID: 32727804
Risk stratification for locally advanced hepatocellular carcinoma using pretreatment alpha-foetoprotein and (18) F-fluoro-2-deoxyglucose positron emission tomography.
Rhee WJ, Hwang SH, Byun HK, Yun M, Han KH, Seong J
Liver Int 2017 Apr;37(4):592-599. Epub 2016 Nov 27 doi: 10.1111/liv.13297. PMID: 27804192

Therapy

Sequential transarterial chemoembolisation and stereotactic body radiotherapy followed by immunotherapy as conversion therapy for patients with locally advanced, unresectable hepatocellular carcinoma (START-FIT): a single-arm, phase 2 trial.
Chiang CL, Chiu KWH, Chan KSK, Lee FAS, Li JCB, Wan CWS, Dai WC, Lam TC, Chen W, Wong NSM, Cheung ALY, Lee VWY, Lau VWH, El Helali A, Man K, Kong FMS, Lo CM, Chan AC
Lancet Gastroenterol Hepatol 2023 Feb;8(2):169-178. Epub 2022 Dec 15 doi: 10.1016/S2468-1253(22)00339-9. PMID: 36529152
Anti-PD-1/PD-L1 immunotherapy in conversion treatment of locally advanced hepatocellular carcinoma.
Chen J, Zhang D, Yuan Y
Clin Exp Med 2023 Jul;23(3):579-590. Epub 2022 Aug 26 doi: 10.1007/s10238-022-00873-6. PMID: 36018466
Arterial Chemotherapy of Oxaliplatin Plus Fluorouracil Versus Sorafenib in Advanced Hepatocellular Carcinoma: A Biomolecular Exploratory, Randomized, Phase III Trial (FOHAIC-1).
Lyu N, Wang X, Li JB, Lai JF, Chen QF, Li SL, Deng HJ, He M, Mu LW, Zhao M
J Clin Oncol 2022 Feb 10;40(5):468-480. Epub 2021 Dec 14 doi: 10.1200/JCO.21.01963. PMID: 34905388
Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial.
Garin E, Tselikas L, Guiu B, Chalaye J, Edeline J, de Baere T, Assenat E, Tacher V, Robert C, Terroir-Cassou-Mounat M, Mariano-Goulart D, Amaddeo G, Palard X, Hollebecque A, Kafrouni M, Regnault H, Boudjema K, Grimaldi S, Fourcade M, Kobeiter H, Vibert E, Le Sourd S, Piron L, Sommacale D, Laffont S, Campillo-Gimenez B, Rolland Y; DOSISPHERE-01 Study Group
Lancet Gastroenterol Hepatol 2021 Jan;6(1):17-29. Epub 2020 Nov 7 doi: 10.1016/S2468-1253(20)30290-9. PMID: 33166497
Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial.
Vilgrain V, Pereira H, Assenat E, Guiu B, Ilonca AD, Pageaux GP, Sibert A, Bouattour M, Lebtahi R, Allaham W, Barraud H, Laurent V, Mathias E, Bronowicki JP, Tasu JP, Perdrisot R, Silvain C, Gerolami R, Mundler O, Seitz JF, Vidal V, Aubé C, Oberti F, Couturier O, Brenot-Rossi I, Raoul JL, Sarran A, Costentin C, Itti E, Luciani A, Adam R, Lewin M, Samuel D, Ronot M, Dinut A, Castera L, Chatellier G; SARAH Trial Group
Lancet Oncol 2017 Dec;18(12):1624-1636. Epub 2017 Oct 26 doi: 10.1016/S1470-2045(17)30683-6. PMID: 29107679

Prognosis

Anti-PD-1/PD-L1 immunotherapy in conversion treatment of locally advanced hepatocellular carcinoma.
Chen J, Zhang D, Yuan Y
Clin Exp Med 2023 Jul;23(3):579-590. Epub 2022 Aug 26 doi: 10.1007/s10238-022-00873-6. PMID: 36018466
Arterial Chemotherapy of Oxaliplatin Plus Fluorouracil Versus Sorafenib in Advanced Hepatocellular Carcinoma: A Biomolecular Exploratory, Randomized, Phase III Trial (FOHAIC-1).
Lyu N, Wang X, Li JB, Lai JF, Chen QF, Li SL, Deng HJ, He M, Mu LW, Zhao M
J Clin Oncol 2022 Feb 10;40(5):468-480. Epub 2021 Dec 14 doi: 10.1200/JCO.21.01963. PMID: 34905388
Integration of Systemic and Liver-Directed Therapies for Locally Advanced Hepatocellular Cancer: Harnessing Potential Synergy for New Therapeutic Horizons.
Bent EH, Wehrenberg-Klee E, Koay EJ, Goyal L, Wo JY
J Natl Compr Canc Netw 2021 May;19(5):567-576. Epub 2020 Oct 1 doi: 10.6004/jnccn.2021.7037. PMID: 34030132
Regional Chemotherapy for Biliary Tract Tumors and Hepatocellular Carcinoma.
Mondaca S, Yarmohammadi H, Kemeny NE
Surg Oncol Clin N Am 2019 Oct;28(4):717-729. Epub 2019 Aug 7 doi: 10.1016/j.soc.2019.06.008. PMID: 31472915Free PMC Article
Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial.
Vilgrain V, Pereira H, Assenat E, Guiu B, Ilonca AD, Pageaux GP, Sibert A, Bouattour M, Lebtahi R, Allaham W, Barraud H, Laurent V, Mathias E, Bronowicki JP, Tasu JP, Perdrisot R, Silvain C, Gerolami R, Mundler O, Seitz JF, Vidal V, Aubé C, Oberti F, Couturier O, Brenot-Rossi I, Raoul JL, Sarran A, Costentin C, Itti E, Luciani A, Adam R, Lewin M, Samuel D, Ronot M, Dinut A, Castera L, Chatellier G; SARAH Trial Group
Lancet Oncol 2017 Dec;18(12):1624-1636. Epub 2017 Oct 26 doi: 10.1016/S1470-2045(17)30683-6. PMID: 29107679

Clinical prediction guides

Sequential transarterial chemoembolisation and stereotactic body radiotherapy followed by immunotherapy as conversion therapy for patients with locally advanced, unresectable hepatocellular carcinoma (START-FIT): a single-arm, phase 2 trial.
Chiang CL, Chiu KWH, Chan KSK, Lee FAS, Li JCB, Wan CWS, Dai WC, Lam TC, Chen W, Wong NSM, Cheung ALY, Lee VWY, Lau VWH, El Helali A, Man K, Kong FMS, Lo CM, Chan AC
Lancet Gastroenterol Hepatol 2023 Feb;8(2):169-178. Epub 2022 Dec 15 doi: 10.1016/S2468-1253(22)00339-9. PMID: 36529152
Anti-PD-1/PD-L1 immunotherapy in conversion treatment of locally advanced hepatocellular carcinoma.
Chen J, Zhang D, Yuan Y
Clin Exp Med 2023 Jul;23(3):579-590. Epub 2022 Aug 26 doi: 10.1007/s10238-022-00873-6. PMID: 36018466
Arterial Chemotherapy of Oxaliplatin Plus Fluorouracil Versus Sorafenib in Advanced Hepatocellular Carcinoma: A Biomolecular Exploratory, Randomized, Phase III Trial (FOHAIC-1).
Lyu N, Wang X, Li JB, Lai JF, Chen QF, Li SL, Deng HJ, He M, Mu LW, Zhao M
J Clin Oncol 2022 Feb 10;40(5):468-480. Epub 2021 Dec 14 doi: 10.1200/JCO.21.01963. PMID: 34905388
Clinical impact of Hypofractionated carbon ion radiotherapy on locally advanced hepatocellular carcinoma.
Shiba S, Shibuya K, Okamoto M, Okazaki S, Komatsu S, Kubota Y, Nakano T, Ohno T
Radiat Oncol 2020 Aug 14;15(1):195. doi: 10.1186/s13014-020-01634-z. PMID: 32795340Free PMC Article
Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial.
Vilgrain V, Pereira H, Assenat E, Guiu B, Ilonca AD, Pageaux GP, Sibert A, Bouattour M, Lebtahi R, Allaham W, Barraud H, Laurent V, Mathias E, Bronowicki JP, Tasu JP, Perdrisot R, Silvain C, Gerolami R, Mundler O, Seitz JF, Vidal V, Aubé C, Oberti F, Couturier O, Brenot-Rossi I, Raoul JL, Sarran A, Costentin C, Itti E, Luciani A, Adam R, Lewin M, Samuel D, Ronot M, Dinut A, Castera L, Chatellier G; SARAH Trial Group
Lancet Oncol 2017 Dec;18(12):1624-1636. Epub 2017 Oct 26 doi: 10.1016/S1470-2045(17)30683-6. PMID: 29107679

Recent systematic reviews

Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma.
Abdel-Rahman O, Elsayed Z
Cochrane Database Syst Rev 2020 Jan 24;1(1):CD011313. doi: 10.1002/14651858.CD011313.pub3. PMID: 31978267Free PMC Article
Efficacy and safety of selective internal radiotherapy versus sorafenib for intermediate-locally advanced hepatocellular carcinoma: a systematic review and meta-analysis.
Zou J, Zhu W, Meng H, Luo P, Zhang J
Expert Rev Gastroenterol Hepatol 2019 Mar;13(3):271-279. Epub 2019 Jan 25 doi: 10.1080/17474124.2019.1570135. PMID: 30791765

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...